Drug Interactions of Verapamil (Calcium Channel Blocker):
© Verapamil is used to treat hypertension, to control angina and to manage certain arrhythmia.
© Verapamil blocks voltage-dependent calcium channels of smooth muscle of blood vessels leading to vasodilation and reduction of vascular resistance useful to treat hypertension. Vasodilation induced by Verapamil is also useful to control Angina by increasing the supply of blood and oxygen to the heart. Verapamil blocks voltage-dependent calcium channels of Sinoatrial (SA node) and Atrioventricular (AV node) nodes to decrease impulse conduction through the AV node and protects the ventricles from atrial tachyarrhythmias.
© Verapamil can interact significantly with drugs such as Dofetilide, Lomitapide, Colchicine, Digoxin, Amiodarone, Adenosine, Beta blockers, Clonidine, Clopidogrel, Droperidol, Fingolimod, Lacosamide, Bupivacaine or Mepivacaine, Dantrolene, Cyclobenzaprine, CYP3A4 Inhibitors, CYP3A4 Inducers, CYP3A4 substrates and P-gp Substrates.
© Use of Verapamil in patients taking Dofetilide is contraindicated due to the elevated risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
© Concomitant use of Verapamil and Lomitapide is contraindicated due to increased risk of Lomitapide toxicity.
© It is contraindicated to use Verapamil and Colchicine in patients with renal or hepatic impairment, due to increased risk of colchicine toxicity (Neuromuscular toxicity, etc.)
© The risk of digitalis toxicity is increased by the coadministration of Verapamil with Digoxin.
© Bradycardia, Atrioventricular block and/or Sinus arrest may occur due to the interaction Verapamil with Amiodarone.
© Concomitant use of Verapamil with Adenosine may elevate the risk of ventricular fibrillation.
© When Verapamil is used along with Beta blockers, Hypotension and Bradycardia might be resulted due to additive cardiac effects.
© Use of Verapamil and Clonidine together may lead to increased incidence of sinus bradycardia.
© The risk of thrombotic events is increased by the concomitant use of Verapamil and Clopidogrel.
© Coaministration of Verapamil with Droperidol may elevate the risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
© Severe bradycardia or heart block may occur as a result of combination of Verapamil and Fingolimod.
© The risk of PR interval prolongation, atrioventricular block, or bradycardia increased by the concomitant use of Verapamil with Lacosamide.
© Administration of Verapamil in patients taking Bupivacaine or Mepivacaine, may increase the risk of heart block.
© Severe hyperkalemia with cardiovascular collapse may result due to the administration of Verapamil along with Dantrolene.
© Concomitant use of Verapamil and Cyclobenzaprine may increase the risk of serotonin syndrome.
© Verapamil is a CYP3A4 substrate and the risk of it’s toxicity may be elevated by CYP3A4 inhibitors including Amiodarone, Clarithromycin, Erythromycin, Ketoconazole, Cobicistat, Ceritinib, Atazanavir, etc.
© The therapeutic efficacy of Verapamil might be lost due to the addition of CYP3A4 inducers such as Carbamazepine, Eslicarbazepine, Primidone, Mitotane, Dabrafenib, etc.
© Verapamil is also a weak CYP3A4 inhibitor and it can increase the plasma concentrations of CYP3A4 substrates such as Simvastatin, Atorvastatin, Lovastatin, Apixaban, Domperidone, Donepezil, Dronedarone, Clozapine, Fentanyl, Hydrocodone, Piperaquine, Erlotinib, Nilotinib, Crizotinib, Bosutinib, Ibratinib, Doxorubicin, Simeprevir, Lurasidone, Ranolazine, Eplerenone, Everolimus, Aripiprazole, Eliglustat, Cilostazol, Tolvaptan, etc.
© Verapamil is a P-gp inhibitor and it can increase the plasma concentrations of P-gp substrates such as Dabigatran, Apixaban, Everolimus, Vincristine, Nilotinib, Afatinib, Trabectedin,
